ICER finds unsubstantiated drug price increases cost US $1.67B in 2020, but overall net increases lower than years past
The Institute for Clinical and Economic Review on Tuesday morning released its latest on “unsupported” drug price increases for seven top treatments, and how even after rebates and other concessions, these increases cost the US health system an additional $1.67 billion, including almost $1.4 billion from AbbVie’s Humira alone.
The authors of the report winnowed down a list of the top 250 drugs with the largest US net sales revenue in 2020 to just 10 drugs and assessed whether there was even the potential for evidentiary support to back the price increases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
